Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

Bayer BAYRY announced that the FDA has granted full approval to oncology drug, Vitrakvi (larotrectinib), a first-in-class TRK ...